<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00709449</url>
  </required_header>
  <id_info>
    <org_study_id>OPHT-011007</org_study_id>
    <nct_id>NCT00709449</nct_id>
  </id_info>
  <brief_title>An Open Study Comparing the Effects of Moxaverine on Ocular Blood Flow in Patients With Age- Related Macular Degeneration, Primary Open Angle Glaucoma and Healthy Control Subjects</brief_title>
  <official_title>An Open Study Comparing the Effects of Moxaverine on Ocular Blood Flow in Patients With Age- Related Macular Degeneration, Primary Open Angle Glaucoma and Healthy Control Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A number of common eye diseases such as age-related macular degeneration and glaucoma are&#xD;
      associated with ocular perfusion abnormalities. Although this is well recognized there is not&#xD;
      much possibility to improve blood flow to the posterior pole of the eye in these diseases.&#xD;
&#xD;
      For many years, moxaverine has been used in the therapy of perfusion abnormalities in the&#xD;
      brain, the heart and the extremities. This is based on a direct vasodilatatory effect of the&#xD;
      drug, but also on the rheological properties of red blood cells. In a recent study the&#xD;
      investigators have shown that intravenous moxaverine increases choroidal blood flow in&#xD;
      healthy young subjects. The present study aims to investigate, whether moxaverine also&#xD;
      improves blood flow in the diseased eye after systemic administration.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Choroidal and optic nerve head blood flow</measure>
    <time_frame>2 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Retrobulbar flow velocities</measure>
    <time_frame>2 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retinal blood flow velocity</measure>
    <time_frame>2 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retinal venous and arterial diameters</measure>
    <time_frame>2 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraocular pressure</measure>
    <time_frame>2 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic and diastolic blood pressure</measure>
    <time_frame>2 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Macular Degeneration</condition>
  <condition>Glaucoma</condition>
  <condition>Regional Blood Flow</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 patients with age related macular degeneration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 patients with primary open angle glaucoma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 age and sex matched control subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>moxaverine</intervention_name>
    <description>intravenous infusion of 150 mg in 250 ml NaCl, applied over 30 minutes.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Collateral i</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>moxaverine</intervention_name>
    <description>intravenous infusion of 150 mg in 250 ml NaCl, applied over 30 minutes.</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Collateral i</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>moxaverine</intervention_name>
    <description>intravenous infusion of 150 mg in 250 ml NaCl, applied over 30 minutes.</description>
    <arm_group_label>3</arm_group_label>
    <other_name>Collateral i</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women aged over 50 years&#xD;
&#xD;
          -  Ametropia of less than 6 diopters and anisometropia of less than 2 diopters&#xD;
&#xD;
          -  Clear non-lenticular ocular media&#xD;
&#xD;
        AMD patients:&#xD;
&#xD;
          -  Patients with nonexudative AMD&#xD;
&#xD;
          -  Visual acuity in the study eye &gt; 20/60&#xD;
&#xD;
        Glaucoma patients:&#xD;
&#xD;
          -  Unilateral or bilateral primary open angle glaucoma&#xD;
&#xD;
          -  At least 3 reliable visual field testings&#xD;
&#xD;
          -  Treated intraocular pressure &lt; 21 mmHg,&#xD;
&#xD;
          -  Visual field mean deviation MD &lt;10 (Humphrey 30-2)&#xD;
&#xD;
        Healthy control subjects:&#xD;
&#xD;
          -  Age- , gender- and sex- matched to the two patient groups,&#xD;
&#xD;
          -  Matched with regard to smoking habits of the two patient group&#xD;
&#xD;
          -  No observable eye diseases&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History or presence of gastrointestinal, liver or kidney disease, or other conditions&#xD;
             known to interfere with distribution, metabolism or excretion of the study drug&#xD;
&#xD;
          -  Blood donation during the previous 3 weeks&#xD;
&#xD;
          -  Abuse of alcoholic beverages or drugs, participation in a clinical trial in the 3&#xD;
             weeks preceding the study&#xD;
&#xD;
          -  Known diabetes mellitus&#xD;
&#xD;
          -  Presence of any ocular pathology that interferes with the aims of the present study&#xD;
&#xD;
          -  Intraocular surgery within the last 3 weeks&#xD;
&#xD;
          -  Hypersensitivity to moxaverine&#xD;
&#xD;
          -  Acute gastric bleeding, massive cerebral hemorrhage related to stroke&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Clinical Pharmacology, Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>November 2009</verification_date>
  <study_first_submitted>June 27, 2008</study_first_submitted>
  <study_first_submitted_qc>July 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 3, 2008</study_first_posted>
  <last_update_submitted>November 30, 2009</last_update_submitted>
  <last_update_submitted_qc>November 30, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 1, 2009</last_update_posted>
  <responsible_party>
    <name_title>Gerhard Garh√∂fer, MD</name_title>
    <organization>Department of Clinical Pharmacology, Medical University of Vienna</organization>
  </responsible_party>
  <keyword>Age-related macular degeneration</keyword>
  <keyword>Glaucoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Papaverine</mesh_term>
    <mesh_term>Moxaverine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

